IBRANCE

The Summary of Product Characteristics (SPC) for IBRANCE (palbociclib), hard capsule or film-coated tablet (75 mg, 100 mg or 125 mg), is available  here. 

IBRANCE (palbociclib) is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:

• in combination with an aromatase inhibitor;
• in combination with fulvestrant in women who have received prior endocrine therapy.

In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.